SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending following a Q4 earnings beat and optimistic 2026 delivery guidance driven by its upcoming R2 SUV launch, which has prompted an analyst upgrade. The community is actively debating a potential short squeeze as bulls anticipate significant growth while bears eye future profitability challenges.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending sharply lower following its earnings report and a disappointing revenue outlook, sparking a heated debate among investors. The community is divided on whether this signals a buying opportunity for the increasingly profitable company or reflects growing concerns over competition from prediction markets and future growth challenges in the online gambling sector.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy`s Co

Wendy's is trending as a weak 2026 outlook overshadows an EPS beat, fueling investor debate on the company's future strategy amid concerns about U.S. sales and its protracted CEO search. While some see deep value, an attractive dividend, and short-squeeze potential, others express frustration over declining performance and management's direction.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending following its latest earnings report, which saw the company beat adjusted profit expectations despite a GAAP net loss and revenue miss, alongside a substantial stock buyback announcement. Community sentiment is sharply divided, with some viewing the positive adjusted results and management's bullish outlook on diversification and future growth as a potential bottom and catalyst for a relief rally, while others caution the stock is in a bull trap given the overall losses and analyst downgrades, all within the context of the broader crypto market's recent volatility.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is trending following its Q4 earnings report, which featured strong user growth but a revenue miss and soft Q1 guidance, leading to a significant stock decline and analyst downgrades. The community is deeply split, with many criticizing the company's performance and management, while others see the sharp dip as an overreaction and a buying opportunity for an undervalued asset with acquisition potential and a strategic shift towards AI.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart (UPST) is trending down significantly despite reporting strong earnings, positive guidance, and a leadership change, fueled by analyst downgrades and a broader fintech sell-off. The community expresses extreme frustration, attributing the decline to market manipulation and high short interest, while many view the current price as a deeply oversold buying opportunity.

Toast, Inc. engages in the development and provision of consumer payment application for restaurants. It offers terminals, kiosk, guest facing display, and system accessories. The firm also offers point of sale, reporting and analytics, online ordering and delivery, and kitchen display system. The company was founded by Jonathan Grimm, Aman Narang, and Stephen J. Fredette in December 2011 and is headquartered in Boston, MA.

Toast Inc - Ordinary Shares - Class A

Toast Inc

Toast Inc. is trending after a significant post-earnings sell-off, despite reporting a revenue beat, robust guidance, and an increased share buyback program. While many in the community are using "burnt toast" puns to express frustration, some investors see an overblown market reaction to solid fundamentals and a strong buy opportunity amidst the broader "AI killing software" narrative impacting the sector.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the Platform and Devices segments. The Platform segment includes digital advertising and related services including the demand-side platform and content distribution services such as subscription and transaction revenue shares, media and entertainment promotional spending, the sale of premium subscriptions, and the sale of branded channel buttons on remote controls. The Devices segment is involved in the sale of streaming players, audio products, smart home products, and accessories that are sold through retailers and distributors, as well as directly to customers through the company’s website. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending sharply upward as its recent strong earnings, driven by robust ad growth and optimistic long-term revenue projections, have ignited a wave of analyst upgrades. The community is abuzz with speculation about significant price appreciation and its increasing appeal as a strategic acquisition target within the rapidly consolidating streaming industry.

Airbnb, Inc. engages in the management and operation of an online marketplace. Its marketplace model connects hosts and guests online or through mobile devices to book spaces. The company was founded by Brian Chesky, Nathan Blecharczyk and Joseph Gebbia in 2007 and is headquartered in San Francisco, CA.

Airbnb Inc - Ordinary Shares - Class A

Airbnb Inc

Airbnb is a hot topic as investors digest mixed Q4 earnings, where robust revenue and optimistic forward guidance are being weighed against an an EPS miss, sparking intense community discussion about whether new growth initiatives, including hotel integration and AI, can finally propel the stock past its stagnant trading history.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Despite reporting stellar earnings that surpassed expectations, Applovin is experiencing a sharp pullback, triggering widespread community discussion about perceived market manipulation and broader investor fears surrounding AI's impact on the software sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment...

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma TransCode Therapeutics Announces Publication of Preclinical Data...

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors...

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial TransCode...

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot...

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO TransCode Therapeutics presents preliminary data from its completed...

TransCode Therapeutics, Inc. (RNAZ) on Wednesday said that it has entered into a definitive agreement to acquire privately-held biotech firm Polynoma LLC from CK Life Sciences.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/transcode-therapeutics-rnaz-announces-the-acquisition-of-polynoma-and-a-25-million-strategic-financing-by-a-subsidiary-of-ck-life-sciences-to-form-a-first-in-class-unique-immuno-oncology-and-metastatic-prevention-oncology-compa-302578286.html">announced</a> a $25 million investment from CK Life Sciences, expected to be used to advance the clinical development of its lead microRNA asset called TTX-MC138 into a mid-stage clinical trial. The candidate is believed to be a master regulator of metastatic cancer across multiple indications.Shares of the company soared 55% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNAZ">RNAZ stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Polynoma is developing a late-stage candidate called seviprotimut-L, a vaccine aimed at melanoma patients who have limited options in stage IIB and IIC.“Between the two programs, we see a unique potential to augment seviprotimut-L's focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients," TransCode’s new CEO, Philippe Calais, said.TransCode on Wednesday also announced that Calais has been appointed as the company CEO while remaining Chairman of the Board of Directors. Tom Fitzgerald stepped down as Interim CEO but remains CFO, it added.While there are no other changes to TransCode’s executive team, the company expects to retain several finance, development, and manufacturing professionals from Polynoma, it added.RNAZ stock is down by 87% this year and by 97% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stifel-hikes-price-target-on-tesla-after-fsd-v14-roll-out/ch6EKRbR3i9">Stifel Hikes Price Target On Tesla After FSD V14 Roll Out, Reiterates Hopes In Robotaxi</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 

Equity

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 


Shares of TransCode Therapeutics Inc surged nearly 39% on Thursday after the company announced encouraging progress in its Phase 1a clinical trial of TTX-MC138, an experimental therapy targeting metastatic cancer.TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b (miR-10b), a genetic target believed to play a critical role in the emergence and progression of several metastatic cancers.&nbsp;According to TransCode, 13 patients have been treated with TTX-MC138 across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.&nbsp;Eight patients remain on study, receiving additional doses during each 28-day treatment cycle, and two patients have been on therapy for approximately seven months with stable disease observed.No dose-limiting toxicities or significant safety concerns have been reported in the trial. Preliminary pharmacokinetic and pharmacodynamic data also align with earlier preclinical and Phase 0 findings.&nbsp;The results support advancing to the planned Phase 1b dose expansion, where researchers will further evaluate safety and early anti-tumor signals.The company’s financial position has been a key focus. As of April 2025, TransCode reported a cash balance of $5.81 million, with total liabilities exceeding assets by $2.02 million.&nbsp;Recent fundraising has helped shore up liquidity, including a $10.05 million registered direct offering in March 2025 and a $7.19 million equity raise in January.&nbsp;Last week, H.C. Wainwright lowered its price target on TransCode to $10 from $20 while maintaining a ‘Buy’ rating, according to The Fly.The firm cited recent equity raises as the reason for the revision but noted that its updated model assumes current funds are sufficient to support operations into 2026.Retail enthusiasm was evident on Stocktwits as sentiment was described as ‘extremely bullish,’ with message volume reaching ‘extremely high’ levels.&nbsp;Traders speculated on further upside, with some suggesting the stock could soon surpass the $1 mark and noting bullish chart patterns that could support another leg higher in after-hours trading.<stembedurl>https://stocktwits.com/ProfessorDman1/message/613317226</stembedurl><stembedurl>https://stocktwits.com/al_fred/message/613270466</stembedurl>Despite Thursday’s sharp rebound, TransCode shares remain down 84% year-to-date, far underperforming the broader market.&nbsp;By comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

An electronic board displays information on recent fluctuations of market indices at the B3 Stock Exchange in Sao Paulo, Brazil, on April 7, 2025. (Photo by Cris Faga/NurPhoto via Getty Images)

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns. 

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

With earnings season underway and rate-cut expectations shifting, the next move in the S&P 500 could set the tone for 2026. Are bulls still in control, or is volatility about to pick up? Cast your vote.

RNAZ
TransCode Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest RNAZ News

RNAZTransCode Therapeutics Inc